Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors (Q64151329)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors |
clinical trial |
Statements
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (English)
0 references
26 December 2016
0 references
30 April 2022
0 references
36
0 references
12 month
0 references
21 year
0 references